Actively Recruiting
ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression
Led by Stanford University · Updated on 2026-03-05
162
Participants Needed
2
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.
CONDITIONS
Official Title
ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent form provided
- Willingness to comply with all study procedures and available for the entire study
- Male or female
- Age between 18 and 60 years
- Fluent and literate in English
- Diagnosis of major depressive episode (MDE) and current or recurrent nonpsychotic major depressive disorder (MDD) based on MINI Plus
- PHQ-8 score of 10 or higher at screening, including anhedonia or persistent negative mood symptoms
- Meets criteria for cognitive dysfunction (C+ subgroup) or absence of cognitive dysfunction (C- subgroup) based on cognitive testing and fMRI
You will not qualify if you...
- Diagnosis of bipolar disorder, psychosis, moderate to severe alcohol or substance use disorder, PTSD, OCD, ADHD, or eating disorders
- Active suicidal plan
- Severe vision, hearing, or hand movement impairment
- Medical illness or brain injury interfering with assessments
- Pregnant, breastfeeding, or unwilling/unable to use birth control (for females of childbearing potential)
- Contraindications to 3.0T MRI scanning (e.g., metal in body, claustrophobia)
- Participation in other intervention studies
- Current use of psychotropic medications contraindicated with guanfacine or sertraline
- Medical conditions deemed unsafe for study participation, including specific cardiac, renal, hepatic, and thyroid abnormalities
- Use of substances unsafe with guanfacine
- Use of strong CYP3A4 inhibitors or inducers that cannot be safely stopped
- Unwillingness to verify biotype classification via fMRI
- Unwillingness or inability to use or access a computer for assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Stanford Psychiatry and Behavioral Sciences Department
Palo Alto, California, United States, 94305
Actively Recruiting
2
University of Illinois at Chicago
Chicago, Illinois, United States, 60607
Actively Recruiting
Research Team
L
Leyla Boyar, BA
CONTACT
I
Isabelle Wydler Clinical Research Coordinator, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here